Page last updated: 2024-10-30

losartan and Uremia

losartan has been researched along with Uremia in 14 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs."9.09[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999)
"The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs."5.09[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999)
" Transcriptional screening of ACE-overexpressing monocytes revealed noticeably increased expression of Angiotensin II receptors and adhesion- as well as atherosclerosis-related ICAM-1 and VCAM1."3.80Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism. ( Fiedler, R; Girndt, M; Seibert, E; Trojanowicz, B; Ulrich, C, 2014)
" Losartan significantly attenuated the expression of TGF-β1 and Snail, and decreased kidney fibrosis induced by IS and PCS in vivo."3.78Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. ( Chang, SC; Sun, CY; Wu, MS, 2012)
"Uremia was induced in apoE-/- mice by 5/6 nephrectomy (NX)."1.34Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. ( Binder, CJ; Bro, S; Nielsen, LB; Olgaard, K; Witztum, JL, 2007)
"Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP."1.33Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (14.29)18.2507
2000's5 (35.71)29.6817
2010's5 (35.71)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Kovács, ZZA1
Szűcs, G1
Freiwan, M1
Kovács, MG1
Márványkövi, FM1
Dinh, H1
Siska, A1
Farkas, K1
Kovács, F1
Kriston, A1
Horváth, P1
Kővári, B1
Cserni, BG1
Cserni, G1
Földesi, I1
Csont, T1
Sárközy, M1
Wei, S1
Sun, J1
Li, Y1
Xu, K1
Wang, M1
Zhang, Y1
Uchiyama, H1
Tsujimoto, M2
Shimada, N1
Tsutsui, K1
Nitta, A1
Yoshida, T1
Furukubo, T2
Izumi, S2
Yamakawa, T2
Tachiki, H1
Minegaki, T1
Nishiguchi, K2
Trojanowicz, B1
Ulrich, C1
Seibert, E1
Fiedler, R1
Girndt, M1
Higuchi, K1
Shima, D1
Yokota, H1
Otagiri, M1
Hirata, S1
Takara, K1
Reyes, M1
Benet, LZ1
Sun, CY1
Chang, SC1
Wu, MS1
Wolf, SC1
Sauter, G1
Risler, T1
Brehm, BR1
Lavoie, P1
Robitaille, G1
Agharazii, M2
Ledbetter, S1
Lebel, M3
Larivière, R3
Rodrigue, ME1
Bro, S1
Binder, CJ1
Witztum, JL1
Olgaard, K1
Nielsen, LB1
Cohen, LS1
Friedman, EA1
Cice, G1
Ferrara, L1
Tagliamonte, E1
Russo, PE1
Di Benedetto, A1
Iacono, A1
Dumont, Y1
D'Amours, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Role of Monocytes Adhesion and Vascular Lesions in Vascular Access Success or Failure in Uremic Patients[NCT03231410]30 participants (Anticipated)Observational2017-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for losartan and Uremia

ArticleYear
[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cardiologia (Rome, Italy), 1999, Volume: 44, Issue:12

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood

1999

Other Studies

13 other studies available for losartan and Uremia

ArticleYear
Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
    Scientific reports, 2021, 09-01, Volume: 11, Issue:1

    Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Antihypertensive Agents; Cardiomyopathie

2021
Losartan Attenuates Atherosclerosis in Uremic Mice by Regulating Treg/Th17 Balance via Mediating PTEN/PI3K/Akt Pathway.
    Nephron, 2022, Volume: 146, Issue:5

    Topics: Animals; Atherosclerosis; Disease Models, Animal; Interleukin-10; Interleukin-17; Interleukin-6; Los

2022
Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells.
    Toxins, 2018, 01-25, Volume: 10, Issue:2

    Topics: Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;

2018
Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A

2014
Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.
    The Journal of pharmacy and pharmacology, 2010, Volume: 62, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydroxylases; Cresols; Cytochrome P-450 CY

2010
Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.
    Journal of pharmaceutical sciences, 2011, Volume: 100, Issue:9

    Topics: Animals; Area Under Curve; Biopharmaceutics; Chromatography, Liquid; Estrone; Hepatocytes; Humans; K

2011
Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Angiotensinogen; Animals; Cresols; Epithelial-Mesenchymal Transition; Fibrosis; Gene Expression Regu

2012
Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
    Renal failure, 2005, Volume: 27, Issue:4

    Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit

2005
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.
    Journal of hypertension, 2005, Volume: 23, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta, Thoracic; Blood Pressure; Blott

2005
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    American journal of hypertension, 2006, Volume: 19, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype

2006
Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodi

2007
Losartan-induced azotemia in a diabetic recipient of a kidney transplant.
    The New England journal of medicine, 1996, May-09, Volume: 334, Issue:19

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;

1996
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.
    Journal of hypertension, 2001, Volume: 19, Issue:8

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Endothelin-1; En

2001